Compare LOAN & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | TIL |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 54.8M |
| IPO Year | 1999 | 2021 |
| Metric | LOAN | TIL |
|---|---|---|
| Price | $4.23 | $8.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 24.3K | ★ 30.1K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $8,666,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $5.67 |
| 52 Week High | $5.85 | $42.75 |
| Indicator | LOAN | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 50.03 |
| Support Level | $4.14 | $7.95 |
| Resistance Level | $4.48 | $8.30 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 27.50 | 62.16 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.